<DOC>
	<DOC>NCT00508469</DOC>
	<brief_summary>The purpose of the study is to compare adherence in patients on a fixed combination of travoprost 0.004%/timolol 0.5% and patients on a concomitant combination of travoprost 0.004% and timolol 0.5% using the Travalert® device.</brief_summary>
	<brief_title>Adherence Assessment With Travalert Dosing Aid</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<mesh_term>Timolol</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<criteria>Diagnosis of openangle glaucoma or ocular hypertension; Inadequate control with betablocker or prostaglandin monotherapy and starting therapy with travoprost 0.004% and timolol 0.05%; Intraocular pressure (IOP) at the screening visit in at least one eye ≥ 19 mmHg but not exceeding 36 mmHg in either eye; Other protocoldefined inclusion criteria may apply. Females of childbearing potential currently pregnant, breastfeeding, or not taking control measures to prevent pregnancy; Not currently receiving treatment for lowering IOP with betablockers or prostaglandin analogs; Currently on therapy or was in therapy with another investigational agent within 30 days prior to the baseline visit; History of chronic or recurrent severe inflammatory eye disease, or history of ocular trauma within the past six (6) months, or history of ocular infection or ocular inflammation within the past three (3) months in either eye; History of clinically significant or progressive retinal disease or history of any other severe ocular pathology in either eye that would preclude the administration of a topical prostaglandin analogue; History of severe or serious hypersensitivity to prostaglandin drugs or their analogues, to topical or systemic betablockers, or to any components of the study medication; Intraocular surgery within the past six (6) months or ocular laser surgery within the past three (3) months as determined by patient history and/or examination in either eye; Any abnormality preventing reliable applanation tonometry of either eye; Bestcorrected visual acuity worse than 20/30 Snellen in either eye; Use of any additional topical or systemic ocular hyposensitive medication during the study; Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Intraocular pressure</keyword>
	<keyword>Open-angle glaucoma</keyword>
	<keyword>Ocular hypertension</keyword>
	<keyword>Adherence</keyword>
	<keyword>Compliance</keyword>
</DOC>